Taking phosphate binders may lower the risk of osteoporotic fractures in patients initiating dialysis. Oral phosphate binders may decrease the risk for osteoporotic fracture in patients starting ...

Nicotinamide and Lanthanum Carbonate and Changes in Serum Phosphate and Fibroblast Growth Factor-23 in Patients With CKD: The COMBINE Trial Inclusion criteria for this randomized, double-blind, ...

In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders. Phosphate binders do not appear to substantially affect ...

ISTANBUL, Turkey — The investigational drug PA21 controls hyperphosphatemia over the long term and has a lower pill burden than sevelamer carbonate, according to a phase 3 study. The cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Of survey respondents, 47% said large number and large size of pills were among top phosphate binder adherence ...

Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators. Patients who express greater difficulty, inconvenience, ...

LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...

Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine. Tenapanor may reduce the number of phosphate binder pills patients on hemodialysis (HD) take daily to ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

Following a large-scale clinical trial, researchers have found that lanthanum carbonate does not reduce the risk of cardiovascular disease developing in patients with chronic kidney disease. The drug ...

A panel of kidney and cardiovascular experts Tuesday told the FDA that phosphate binders used to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis should be ...